Skip to main content

Market Overview

FDA Strikes Out CorMedix's DefenCath Application


The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-related bloodstream infections.

  • FDA noted concerns at the third-party manufacturing facility after reviewing records, though the agency did not specify the issues.
  • CorMedix will request a meeting with the FDA, which is estimated to happen by mid-April.
  • The company intends to obtain a plan to resolve the problems when the FDA informs the specific concerns.
  • Additionally, FDA requires a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume within specifications.
  • FDA did not request additional clinical data and did not identify any efficacy or safety data deficiencies.
  • The draft labeling discussed with the FDA added that the initial approval would be for the limited population of patients with kidney failure receiving chronic hemodialysis through a central venous catheter.
  • Price Action: CRMD shares trading is halted, to resume at 9 am ET.

Related Articles (CRMD)

View Comments and Join the Discussion!

Posted-In: bloodstream infectionsBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at